Krónikus limfoid leukémia (CLL): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BTK 26
• CD19 33
• BCL-2 10
• TP53 3
• CD20 10
• CD22 6
• ABL1 2
• PI3K 1
• NOTCH1 0
• CXCR4 0
• STAT3 0
• CD123 1
• CD38 1
• HMGB1 0
• PD-1 0
• PD-L1 0
• EGFR 0
• HDAC 0
• MDM2 0
• PPAR 0
• TIM-3 0
• AKT 0
• ALK 0
• ATM 0
• BCMA 1
• BDNF 0
• BRAF 0
• BRD4 0
• CD30 0
• CD47 0
• CSF1R 1
• CTNNB1 0
• ERK 0
• FAK 0
• FLT3 0
• IDH 0
• IL-23 0
• IL-4 0
• KMT2A 0
• MAPK 0
• MMP-9 0
• NLRP3 0
• NRAS 0
• PCSK9 0
• PRMT5 0
• TLR4 0
• VEGF 0

611 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, Egyesült Államok· 390 447 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Rationally directed therapy for CLL

  University of Tx Md Anderson Can Ctr· Houston, Egyesült Államok· 690 011 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, Egyesült Államok· 2 197 943 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NCI · R41

  Development of MCL 1-Targeting Antibody–Drug Conjugates for Cancer Therapy

  Immunogenic Cancer Engineering Therapeutics Llc· Englewood Cliffs, Egyesült Államok· 412 351 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NEI · R01

  Discovery of novel trifunctional hybrid compounds (TFHCs): potential glaucoma therapy with superior IOP reduction and neuroprotection

  Creighton University· Omaha, Egyesült Államok· 576 730 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-ERC

  Signaling and Powering Anti-cancer Responses in T Cells SPARC

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 2 500 000 EUR· until 2031. okt.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Immuno-Modulatory Platform for Advanced CLL Therapy (IMPACT)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 150 000 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Csehország· EU contribution 150 000 EUR· until 2028. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A single-cell-based solution for an early diagnosis of Richter transformation in patients with chronic lymphocytic leukemia (earlyRTdx)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spanyolország· EU contribution 150 000 EUR· until 2027. okt.

10 of 143 running projects, newest first. Listed amounts together: 97,4 M USD + 16,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  64Cu-LLP2A for Imaging Hematologic Malignancies

  NCT06636175· Washington University School of Medicine· Frissítve: 2026. okt. 16.

  “Loss of further funding”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Beijing Boren Hospital· Frissítve: 2026. okt. 15.

  “No participants.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

  NCT06680661· Leland Metheny· Frissítve: 2026. szept. 10.

  “insufficient funding”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

  NCT05400122· David Wald· Frissítve: 2026. júl. 14.

  “Drugs unavailable”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Frissítve: 2026. júl. 14.

  “This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

  NCT05515406· Ono Pharmaceutical Co., Ltd.· Frissítve: 2026. máj. 29.

  “The study was terminated due to a strategic decision to discontinue development.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

  NCT01962636· Masonic Cancer Center, University of Minnesota· Frissítve: 2026. máj. 20.

  “No longer a research question to answer.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

  NCT03246906· Fred Hutchinson Cancer Center· Frissítve: 2026. máj. 14.

  “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Sun Pharma Advanced Research Company Limited· Frissítve: 2026. máj. 13.

  “Closed for administrative, non-safety-related reasons.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

  NCT06662227· Wondercel Biotech (ShenZhen)· Frissítve: 2026. máj. 7.

  “Because the implementation of the new regulation policy by the Chinese authority”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

  NCT03737981· National Cancer Institute (NCI)· Forrás

• A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT05057494· AstraZeneca· Forrás

• A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

  NCT07709000· Merck Sharp & Dohme LLC· Forrás

• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

  NCT04301076· National Cancer Institute (NCI)· Forrás

• Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

  NCT01087333· National Cancer Institute (NCI)· Forrás

• Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

  NCT03701282· National Cancer Institute (NCI)· Forrás

• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  NCT04269902· National Cancer Institute (NCI)· Forrás

• A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· BeOne Medicines· Forrás

• Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

  NCT06676033· National Heart, Lung, and Blood Institute (NHLBI)· Forrás

• A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

  NCT06524375· Genentech, Inc.· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 21
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 4
• Machine Learning 10
• Cohort Studies 18
• Genome-Wide Association Study 2

• Zanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System-Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report.

  Cancer Rep (Hoboken), 2026. nov.

• Central nervous system involvement of chronic lymphocytic leukaemia with brain and spinal cord infiltration.

  BMJ Case Rep, 2026. aug.

• Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis.

  Leuk Lymphoma, 2026. jún.

• Ophthalmic Artery Vasculitis in VEXAS Syndrome: A Novel, Vision-Threatening Manifestation.

  Ocul Immunol Inflamm, 2026. máj.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.